Jan Stoehlmacher-Williams

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)

Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein et al. · Annals of Oncology · 2014 · 258 citations · Full text

Surgical Oncology, Hepatology, Gastrointestinal Oncology +10

Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Linnea Stenholm, Jan Stoehlmacher-Williams, Salah‐Eddin Al‐Batran et al. · Annals of Oncology · 2013 · 41 citations · Full text

Advanced Gastric Cancer, Medicine, Immunology +11

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

Gunnar Folprecht, Susanne Hamann, Katharina Schütte et al. · BMC Cancer · 2014 · 36 citations · Full text

EGFR, FLT1 and Heparanase as Markers Identifying Patients at Risk of Short Survival in Cholangiocarcinoma

Andreas-Claudius Hoffmann, Eray Goekkurt, Peter V. Danenberg et al. · PLoS ONE · 2013 · 25 citations · Full text

Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.

Jan Stoehlmacher-Williams, Cristian Villanueva, Paolo Foa et al. · Journal of Clinical Oncology · 2012 · 24 citations

Squamous Cell Carcinoma, Immunology, Pathology +22